SPARC Monoclonal antibody, PBS Only

SPARC Monoclonal Antibody for WB, IHC, IF/ICC, Indirect ELISA

Host / Isotype

Mouse / IgG2a

Reactivity

human

Applications

WB, IHC, IF/ICC, Indirect ELISA

Conjugate

Unconjugated

CloneNo.

1A2C1

Cat no : 66426-1-PBS

Print datasheet

Synonyms

Basement membrane protein 40, BM 40, ON, Osteonectin, SPARC



Planning an IHC experiment? We recommend our IHCeasy SPARC Ready-To-Use IHC Kit. SPARC primary antibody included.

产品信息

66426-1-PBS targets SPARC in WB, IHC, IF/ICC, Indirect ELISA applications and shows reactivity with human samples.

Tested Applications WB, IHC, IF/ICC, Indirect ELISA Application Description
Tested Reactivity human
Immunogen SPARC fusion protein Ag7390 种属同源性预测
Host / Isotype Mouse / IgG2a
Class Monoclonal
Type Antibody
Full Name secreted protein, acidic, cysteine-rich (osteonectin)
Synonyms Basement membrane protein 40, BM 40, ON, Osteonectin, SPARC
Calculated Molecular Weight 35 kDa
Observed Molecular Weight 38 kDa, 52 kDa
GenBank Accession NumberBC004974
Gene Symbol SPARC
Gene ID (NCBI) 6678
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
UNIPROT IDP09486
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.
The product is shipped with ice packs. Upon receipt, store it immediately at -80°C

背景介绍

SPARC, also known as ON (Osteonectin) or BM-40 (Basement-membrane protein 40), is an extracellular glycoprotein with the calculated molecular mass of 35 kDa and the apparent molecular mass of 40-43 kDa and 50 kDa (PMID: 7495300, 12365801). SPARC belongs to a group of matricellular proteins defined as secreted components that do not contribute directly to the formation of structural elements but serve to modulate cell-matrix interactions and cellular functions (PMID: 7542656; 12231357). SPARC is expressed at high levels in bone tissue, is distributed widely in many other tissues and cell types, and is associated generally with tissues undergoing morphogenesis, remodeling and wound repair (PMID: 10567433). It elicits changes in cell shape, inhibits cell-cycle progression, and influences the synthesis of extracellular matrix (PMID: 12721366). Altered expression of SPARC has been reported in a variety of cancers, which include breast, ovarian, colorectal, and pancreatic cancer as well as melanoma and glioblastomas (PMID: 18849185).